- Home
- MSN vs MYNZ Comparison
MSN vs MYNZ Comparison
Compare MSN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSN | MYNZ |
|---|---|---|
| Founded | 1948 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 8.8M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MSN | MYNZ |
|---|---|---|
| Price | $0.39 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 40.3K | ★ 195.9K |
| Earning Date | 02-13-2026 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,739,000.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.92 |
| 52 Week High | $0.85 | $8.20 |
Technical Indicators
Market Signals| Indicator | MSN | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 53.19 |
| Support Level | $0.38 | $1.09 |
| Resistance Level | $0.42 | $1.29 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 10.68 | 60.56 |
Price Performance
Historical ComparisonAbout MSN Emerson Radio Corporation
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.